Oncimmune Holdings Company Description

Oncimmune Holdings plc, a precision medicine company, provides autoantibody biomarker profiling in immuno-oncology, autoimmune, and infectious diseases in Europe and internationally.

It offers ImmunoINSIGHTS, an autoantibody profiling service that unlocks the immune system to discover and convert autoantibodies into actionable biomarkers; Sero Tag, a discovery engine which identifies relevant biomarker pool for target discovery or companion diagnostics; NavigAID, a creation of a disease-specific biomarker panel; and Autoantibody Biomarkers, a companion diagnostic biomarker.

The company also provides business development and marketing services. Oncimmune Holdings plc was incorporated in 2015 and is headquartered in Leeds, the United Kingdom.

Oncimmune Holdings plc

Country	United Kingdom
Founded	2015
Industry	Biotechnology
Sector	Healthcare
Employees	38
CEO	Martin Gouldstone

Contact Details

Address: 1 Park Row Leeds, LS1 5AB United Kingdom
Website	oncimmune.com

Stock Details

Ticker Symbol	ONC
Exchange	London Stock Exchange AIM
Fiscal Year	September - August
Reporting Currency	GBP
ISIN Number	GB00BYQ94H38
SIC Code	2835

Key Executives

Name	Position
Martin Gouldstone	Chief Executive Officer
Martin Hudson	Chief Financial Officer
Ron Kirschner	Chief Operating Officer
Cléa Rosenfeld	Head of Investor Relations